Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Rituximab
MabThera
Routinely available
SMC (135/04)
20/03/2001
Indication
Follicular lymphoma in combination with CVP chemotherapy
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
Solution
Comments
March 2005 - Added to the Formulary as a prescribing note, for Specialist Use only.